You need to enable JavaScript to run this app.
FDA’s LDT oversight faces an uncertain future, experts say
Regulatory News
Jeff Craven
CDRH
Diagnostics/IVDs
Laboratory developed tests (LDTs)
Regulatory Intelligence/Policy
United States